Background-Dilated cardiomyopathy (DCM) is a primary disease of the heart muscle associated with sudden cardiac death secondary to ventricular tachyarrhythmias and asystole. However, the molecular pathways linking DCM to arrhythmias and sudden cardiac death are unknown. We previously identified a S196L mutation in exon 4 of LBD3-encoded ZASP in a family with DCM and sudden cardiac death. These findings led us to hypothesize that this mutation may precipitate both cytoskeletal and conduction abnormalities in vivo. Therefore, we investigated the role of the ZASP4 mutation S196L in cardiac cytoarchitecture and ion channel biology. Methods and Results-We generated and analyzed transgenic mice with cardiac-restricted expression of the S196L mutation. We also performed cellular electrophysiological analysis on isolated S196L cardiomyocytes and proteinprotein interaction studies. Ten month-old S196L mice developed hemodynamic dysfunction consistent with DCM, whereas 3-month-old S196L mice presented with cardiac conduction defects and atrioventricular block. Electrophysiological analysis on isolated S196L cardiomyocytes demonstrated that the L-type Ca 2ϩ currents and Na ϩ currents were altered. The pull-down assay demonstrated that ZASP4 complexes with both calcium (Ca v 1.2) and sodium (Na v 1.5) channels. Conclusions-Our findings provide new insight into the mechanisms by which mutations of a structural/cytoskeletal protein, such as ZASP, lead to cardiac functional and electric abnormalities. This work represents a novel framework to understand the development of conduction defects and arrhythmias in subjects with cardiomyopathies, including DCM. (Circ Arrhythm Electrophysiol. 2010;3:646-656.)
D ilated cardiomyopathy (DCM) is the most frequent form of primary cardiomyopathy and one of the leading causes of heart failure. DCM is associated with increased risk of sudden cardiac death (SCD), which accounts for approximately 325 000 deaths per year in the United States alone. 1 Overall, DCM accounts for Ͼ10% of all SCD cases and has a 1-year mortality rate of up to 10% to 50%, and approximately 30% to 50% of these deaths are ventricular tachyarrhythmia-mediated SCD. 1 However, severe bradyarrhythmias, such as asystole and conduction blocks, also contribute to mortality, especially in patients with advanced left ventricular (LV) dysfunction. Replacement of deranged myocardium by fibrous tissues has been proposed as a likely mechanism of reentrant tachycardia and/or conduction disease, but very little is known about the cellular mechanisms connecting cytoskeletal alterations to arrhythmias in DCM. 2 
Clinical Perspective on p 656
The LDB3-encoded human ZASP is a sarcomeric cytoskeletal protein that maintains the structural integrity of the Z-line. [3] [4] [5] [6] Alternative splicing of the LDB3 gene transcript leads to multiple ZASP isoforms, which contain several domains. The PDZ (PSD95, DlgA, and zo-1) domain is common to all ZASP isoforms, whereas the ZASP-like Motif (ZM), encoded by exons 4 and 6/7 (ZM4 and ZM6), and the 3 C-terminal LIM (Lin11, Isl-1 and Mec-3) domains are isoform-specific. 3, 4, 7, 8 ZASP and its murine homolog Cypher present at least 6 isoforms, including ZASP4 in humans and Cypher1c in mice, which contain exon 4. 3, 4, 7, 8 Interestingly, ZASP4 and Cypher1c are highly homologous, cardiacspecific, and abundantly expressed in human and murine hearts, respectively. 3, 4, 7, 8 Previous research showed that germline and cardiomyocyte-restricted ablation of Cypher precipitated severe DCM, Z-line derangement and premature death within the first weeks of life secondary to both congestive heart failure and arrhythmic SCD. 56 More recently, we demonstrated a family with DCM secondary to a novel missense mutation, S196L, in ZASP4 (S196L). 3 S196 resides in the cardiac-specific exon 4. Intriguingly, the proband presented with severe ventricular dysfunction and LV chamber dilation, whereas a brother died with precardiomyopathic SCD. These findings suggest that further investigations of ZASP4 biology will provide key insights on how cytoskeletal alterations lead to arrhythmias in patients with DCM.
We hypothesized that S196L underlies both cardiomyopathy and arrhythmias caused by cytoskeletal perturbation for the former and acquired ion channel dysfunction for the latter. To test our hypothesis in vivo, we generated transgenic mice with the murine cardiac-specific ␣-myosin promoter driving the expression of wild-type ZASP4 (WT) or S196L. We reasoned that this approach would be well tolerated because ZASP4 is highly homologous to the murine Cypher isoform (Cypher1c) while maintaining the functional properties of the human protein in vivo. We selected the ␣-MHC promoter because of its cardiac-restricted expression pattern and to avoid embryonic lethality due to germline ablation of Cypher. 5 Our results show that S196L is associated with hemodynamic impairment and ion channel dysfunction and suggest, for the first time, to our knowledge, that ZASP4 is a key molecule linking cytoskeletal alterations to rhythm disturbances in DCM patients.
Methods

Plasmid Construction and Generation of Transgenic Mice
The full-length ZASP4-WT 2,184 bp cDNA sequence was amplified using human cardiomyocyte cDNA as a template and cloned into a vector containing the mouse ␣-myosin heavy chain (␣-MHC) promoter and conjugated with 6His-V5 tag. The S196L mutation was generated using the following mutagenesis primers: forward, CCT-GCCGGGCTTGAGCCAGCCGAG; reverse, CTCGGCTGGCT-CAAGCCCGGCAGG, following the Quikchange site-Directed Mutagenesis protocol from Stratagene. The linearized plasmids of both ZASP4-WT and S196L DNA were injected into fertilized oocytes (2-cell blastocyst stage) derived from C57/BL (6J) mice, and then the oocytes were transferred into the oviducts of pseudopregnant FVB mice: These were performed by the Transgenic and Homologous Recombination Core Facility of Baylor College of Medicine. The ␣-MHC promoter is the most used and worldwide accepted system to provide cardiac-restricted expression in mice hearts. Transgenic mice were identified by polymerase chain reaction.
Echocardiography Assessment of Cardiac Function
A commercial high-resolution ultrasonic system (Vevo 770, Visual Sonics, Toronto, Ontario, Canada) equipped with a 30-MHz mechanical probe was used for echocardiography. The mice were placed on a warming platform in a supine position and were anesthetized by mask inhalation of isoflurane, and ECG limb electrodes were placed. The chests were cleaned with a chemical hair remover to minimize ultrasound attenuation. Aquasonic 100 gel (Parker Laboratories) was applied to the thorax surface to optimize visibility of the cardiac chambers. The heart was first imaged in the 2D mode in the parasternal long-axis view. From this view, an M-mode cursor was positioned perpendicular to the interventricular septum and posterior wall of the LV at the level of the papillary muscles, and M-mode images were obtained for off-line measurement of wall thickness and chamber dimensions. IVSDs (interventricular septum diameter in systole), IVSDd (interventricular septum diameter in diastole), LVP 
MRI Assessment of Cardiac Function
MRI images were acquired using the Bruker Biospin 7T horizontal MR scanner (Ettlingen, Germany). We sedated the animals for the procedure using isoflurane and we monitored heart rate, respiratory rate, and body temperature continuously throughout the study. Both ECG and respiratory-triggered cine gradient echo images were acquired using the short-axis and 4-chamber geometries. Fourteen to 18 images were acquired for each cardiac cycle depending on the heart rate. Images were acquired using a FOV of 3.4 cm 2 , slice thickness of 1 mm, and an in-plane resolution of 135 m. Usually, 10 to 12 images are required for a typical volumetric image set covering both ventricles. Custom designed software for standard planimetry techniques (ImageJ, National Institutes of Health; Bethesda, Md) was used to analyze off-line images. Both right and left ventricular endocardial and epicardial contours were drawn on each of the 10 to 12 short-axis slices, and the contour data were used to calculate the volumes.
The right ventricular thickening was calculated by first drawing 5 radial bisectors from the endocardial to the epicardial contour of the right ventricle. These were drawn in both diastole and systole. The thickening is calculated as the [thickness (systole)Ϫthickness (diastole)]/thickness (diastole). The thickening reported for each animal is the average thickening of the 5 radii.
ECG Measurements
The nontransgenic littermate controls (NTG), WT, and S196L mice underwent telemetric ECG recordings beginning at 4 months of age. A radiotelemetry transmitter (Model EA-F20, Data Sciences International, St Paul, Minn) was surgically inserted into the peritoneal cavity, with one lead subcutaneously placed at the right shoulder and the other placed at the lower left abdomen. Before recording, mice were allowed to recover for 2 to 3 days, followed by 1 week of recording. The ECG signals were acquired and stored on Dell Optiplex 280 computer using Dataquest A.R.T. system (Data Science International). Tracings were analyzed for heart rate, PR and QRS intervals using Igor software (WaveMetrics, Lake Oswego, Ore).
Cell Isolation and Electrophysiological Analysis
Mice ventricular myocytes were isolated from 4-to 5-month-old NTG, WT, and S196L mice using a nonperfused cardiomyocyte isolation kit (Cellutron Life Technology, Baltimore, Md). Briefly, hearts were harvested, and, after removal of the atria, the ventricles were subjected to washing buffer and then treated with digesting buffer. The digested cells were plated in a Petri dish for 2 hours to exclude fibroblasts. The remaining nonadherent cardiomyocytes were used for the patch-clamp experiments.
Whole-cell configuration of the voltage-clamp technique was used to record sodium (I Na ) and L-type calcium currents (I Ca,L ), as previously described. 9 -15 The glass pipette electrodes were made from Corning 7056 glass capillaries (Warner Instrument, Hammed, Conn) with a pipette resistance of 2Ϸ3 mol/L⍀ in the bath solution. Whole-cell recordings were carried out at ambient temperature (22°Ϸ25°C) for I Na and at 36°C for I Ca,L.
Step-pulse voltages were generated with Axopatch 200B amplifier using Pclamp 9 software (Molecular Device, Sunnyvale, Calif). The recorded currents were filtered using a built-in 4-pole Bessel low-pass filter (cutoff frequency: 10 kHz for I Na and 2 kHz for I Ca,L ) and then digitized at 20 and 5 kHz, respectively. The pipette solution to record I Na contained (mmol): 5 NaF, 115 CsF, 20 CsCl, 10 EGTA, and 10 HEPES (pH 7.35 with CsOH). Bath solution contained (mM): 5 NaCl, 1.0 MgCl 2 , 130 tetraethylammonium (TEA) chloride, 5 CsCl, 10 HEPES, and 10 glucose (pH 7.35 with NaOH). For the I Ca,L recordings, intracellular pipette contained (mmol): 85 Asparatate, 20 TEACl 2 , 2 MgCl 2 , 10 EGTA, 10 HEPES, 5 Mg-ATP, and 5 Na 2 -GTP (pH 7.2 with KOH). Extracellular buffer contained (mM): 135 NaCl, 1 MgCl 2 , 1.8 CaCl 2 , 5.4 KCl, 10 HEPES, and 10 glucose (pH 7.35 with NaOH). Whole-cell currents amplitude and gating kinetics were analyzed using Clampfit (Axon Instruments, Sunnyvale, Calif) and Igor software (WaveMetrics, Lake Oswego, Ore).
Cardiomyocyte Contraction Assessment
Cardiomyocytes were isolated from the LV free wall of Langendorffperfused hearts. Mice were anesthetized with ketamine and xylazine and anticoagulated with heparin (50 U, ip). Hearts were excised rapidly, cannulated, and perfused at 37°C with modified KrebsHenseleit solution (Sigma-Aldrich). Each heart was perfused at a constant hydrostatic pressure resulting in a steady-state flow rate in the range of 2 to 3 mL/min for 3 to 5 minutes and then perfused with additional collagenase (0.5 mg/mL, Worthington type 2) and 0.05 mmol/L Ca 2ϩ . After a 50% to 100% increase of flow rate, the ventricle was excised and cut into small pieces in the same digestion buffer and swirled gently for 3 to 5 minutes to acquire isolated cardiomyocytes. Cell suspensions were filtered to remove undigested tissue and collected by centrifuge at 500 rpm for 2 minutes.
Isolated cardiomyocytes were resuspended in modified KrebsHenseleit solution containing 1.25 mmol/L Ca 2ϩ with 1 mg/mL bovine serum albumin, and stored for up to 3 hours at room temperature for contraction measurement. Cells were attached to coverslips precoated with 10 g/mL laminin and mounted in a perfusion chamber (RC 47 FSLP, Warner Instruments). Cells were then placed on the stage of an inverted microscope (OLYMPUS IX 70) and superfused with the same modified Krebs-Henseleit solution. Cells were paced at 0.5 Hz after an 8-to 10-minute period of stabilization (baseline) and then superfused with additional isoproterenol (1 mol/L; Sigma-Aldrich, St Louis, Mo). Sarcomere motion was recorded continuously using Ionoptix acquisition software and the data were stored for an off-line analysis by IonWizard software (Ionoptix 1999, version 5).
Histology and Immunohistochemistry
Mouse hearts were isolated and continuously perfused with cardioplegic solution containing KCl 3.73 g/L, and 10% neutralized formalin (Sigma-Aldrich) or frozen in liquid nitrogen and stored in Ϫ80°C. Perfused hearts were paraffin-embedded, and 5-m sections were stained with hematoxylin and eosin or Masson trichrome. For cryosections (5 m), mouse hearts were equilibrated in 30% sucrose solution and mounted in O.C.T. (VWR). Sections were fixed with acetone at Ϫ20°C for 10 minutes, followed immunofluorescence staining with primary antibodies (anti-V5-ZASP4 and anti-Na v 1.5 or Ca v 1.2 from Alomone, Jerusalem, Israel) for 1 hour and incubation with corresponding secondary antibodies conjugated with FITC Alexa Flour 488 or Texas Red (Molecular Probes, Invitrogen) for 30 minutes. In addition, heart sections from NTG mice were stained with an anti-ZASP monoclonal antibody generated by Dr Faulkner and recognizing the endogenous Cypher1c homolog, as previously described. 4 Sections were mounted with prolonged gold antifade reagent (Molecular Probes, Invitrogen) and visualized using an Olympus BX51 microscope.
In Vitro Interaction Pull-Down Assay
Interactions between ZASP4 and Na v 1.5 as well as between ZASP4 and Ca v 1.2 were studied with His-tagged pull-down assays (ProFound pull-down PolyHis Protein: Protein Interaction Kit; Pierce). To purify WT and S196L protein, Escherichia coli cells were grown and harvested 24 hours after transformation with ZASP4 WTpcDNA 3.1/V5-His and S196L-pcDNA 3.1/V5-His plasmids. The bacterial pellet was incubated for 30 minutes with ProFound lysis buffer (Pierce) containing protease inhibitor cocktail (Sigma), and centrifuged at 12 000 g for 5 minutes to clarify the crude E coli lysate. The supernatant (300 L) containing wt (His) or S196L (His) was then incubated with immobilized cobalt chelate (Pierce) in a spin column at 4°C for 2 hours. After washing 5 times, the immobilized His-tagged ZASP4-WT or S196L protein was incubated at 4°C for 4 hours with the lysates from neonatal rat myocardium. After extensive washing with washing buffer (Pierce), the proteins were eluted in elution buffer (washing buffer with 290 mmol/L imidazole) and the eluted proteins were separated by SDS-PAGE, and stained with antibodies to the voltage gated pan-sodium channel (Sigma-Aldrich, St Louis, Mo) and Ca v 1.2 (Alomone, Jerusalem, Israel). The pcDNA3.1/V5-His-TOPO/lacZ plasmid (Invitrogen Co) was used as the negative control.
Electron Microscopy Analysis
Once anesthetized, mice hearts were excised immediately and cut into small pieces, then fixed in 3% glutaraldehyde solution and processed according to standard protocol in the Integrated Microscopy Core at Baylor College of Medicine. Images were taken using Hitachi H-7500 Transmission Electron Microscope.
Statistics
Comparison of the data were done using the Kruskal-Wallis test or the Mann-Whitney-Wilcoxon test when appropriate, with PϽ0.05 considered statistically significant. All the data in the text and 
Results
S196L Overexpression Precipitates Hemodynamic Dysfunction
We established 2 separate transgenic mouse lines for both WT and S196L to rule out secondary phenotype effects caused by the random transgene insertion. Expression of the ZASP4-V5 fusion protein generated by the transgene was . C, Histological analyses of hearts from ZASP4 transgenic mice show mild cardiac fibrosis in S196L mice. Cardiac sections from 10-month-old NTG, WT, and S196L mice were stained with Masson trichrome (ϫ200 and ϫ400). Note the mild fibrous tissue present in S196L mice, which was stained blue.
confirmed by immunohistochemistry and Western blot using the anti-V5 antibody, which discriminates the expression of the human ZASP4 isoform from the endogenous Cypher homolog (Supplemental Figure 1) . We selected lines WT-41, S196L-93, and S196L-94, in which the mutated transgene expressed 4 to 6 times the amount of WT protein. Supplemental Figure 1 shows the confocal microcopy analysis of immunohistochemistry using the anti-V5 antibody, which demonstrates that the transgene localized at the Z-line and colocalized with the Z-line marker ACTN2.
The mendelian frequency of newborns WT and S196L transgenic male and female mice was normal, and the lifespan of both genotypes was similar. Growth of NTG, WT, and S196L did not differ, although the latter appeared less active.
Echocardiographic analysis of NTG (nϭ3), WT (nϭ4), and S196L (nϭ6) mice was performed at 4, 7, and 10 months. At 4 and 7 months of age, WT and S196L mice showed no significant difference in cardiac size and systolic function compared with NTG (data not shown), whereas at 10 months, S196L mice developed cardiac dilation and decreased fractional shortening (FS) and ejection fraction (EF) compared with WT and NTG ( Figure 1A-B) . MRI (at 10 months) confirmed that S196L showed LV end-diastolic dilation and decreased LV systolic function ( Figure 1C-D) . Although WT mice showed a slightly increased LVEF and decreased LVEDV compared with NTG, these differences were not statistically significant ( Figure 1C and 1D ). These data show that S196L overexpression in mice leads to severe cardiac dysfunction.
S196L and Abnormal Cardiac Morphology and Histology
Histological studies using hematoxylin and eosin staining from serial myocardial sections demonstrated abnormal gross anatomy in 10-month-old S196L mice with LV dilation (Figure 2A) , with no statistical difference in cardiac mass measurements acquired by MRI in NTG, WT, and S196L mice ( Figure 2B ). Masson trichrome staining denoted mild focal fibrosis in ventricular myocardium of the10-month-old S196L mice compared with NTG and WT mice ( Figure 2C ). These data suggest that ZASP4 mutations are responsible for altering the cytoarchitecture of the working myocardium. Ultrastructural analysis and contractile function in NTG, WT, and S196L mice. A, Electron microscopic images of cardiac sections from NTG, WT, and S196L mice are shown. Note the altered sarcomeric and Z-band structure in S196L mice. Arrows indicate the Z-bands. B, Sarcomeric shortening was performed at both baseline and after isoproterenol infusion showing statistical significant difference in S196L mice cardiomyocytes contractile function compared with NTG and WT myocardial cells after ISO infusion [(NTG baselineϭ9. 24 
S196L Impairs Cardiomyocyte Sarcomeric Contraction
Electron microscopy analysis revealed severe sarcomere derangement and Z-band disorganization in the myocardium of the 10-month-old S196L mice ( Figure 3A) . We reasoned that contractile function may be impaired in these mice and assessed it by studying isolated cardiomyocytes from 10-month-old NTG, WT, and S196L mice at baseline and on stimulation by isoproterenol, as previously published. 16 The percentage of sarcomere shortening was reduced significantly in S196L cardiomyocytes compared with NTG and WT, suggesting an impaired contractile function. This abnormality was not compensated by sympathetic stimulation, as assessed by isoproterenol infusion ( Figure 3B ). Our data provide an ultrastuctural basis for the abnormal morphology and histology associated with ZASP4 mutation and demonstrates that these defects are severe enough to lead to functional abnormalities in affected hearts. In addition, these findings suggest that the functional cardiac derangements associated with mutation of ZASP4 are persistent in different pathophysiological conditions.
ECG Abnormalities in S196L Mice Precede Hemodynamic Changes
The ECG limb electrodes, used when we performed the echocardiogram on the 10-month-old NTG, WT, and S196L mice, detected an altered ECG pattern in S196L mice when compared with WT animals (Supplemental Figure 2) . Therefore, we reasoned that ZASP may represent an important biological factor linking cardiac functional and electric derangements and that ECG abnormalities may also occur before the development of overt hemodynamic dysfunction. To test this hypothesis, we performed ECG studies on conscious 4-month-old NTG, WT, and S196L mice (nՆ6 per group) ( Figure 4A and Table 1 ). The S196L mice demonstrated slower heart rate and prolonged PR and QRS intervals compared with the NTG and WT mice ( Figure 4A and Table  1 ). These abnormalities represent a common finding in patients with DCM, and represent a likely substrate for the development of severe tachyarrhythmias and bradyarrhythmias in this disease. These data show that ZASP is a key factor connecting cytoskeletal and electric myocardial derangements in the working heart.
S196L Alters Both L-Type Calcium Currents and Sodium Currents in Murine Cardiomyocytes
To investigate how the S196L mutation leads to conduction disturbances, we focused our electrophysiological studies on L-type calcium currents (I Ca,L ) and sodium currents (I Na ) because they represent the major currents involved in cardiac conduction and depolarization (I Ca,L and I Na ) and excitationcontraction coupling (I Ca,L ). In addition, previous reports Mice telemetry and cellular electrophysiological analysis. A, Representative ECG traces recorded from 4-month-old NTG, WT, and S196L mice. B-a, Superimposed whole-cell calcium current traces induced by a step pulse protocol (between Ϫ50 and 0 mV for 300 ms from a holding potential of Ϫ80 mV after 40-ms prepulse at Ϫ40 mV). B-b, I-V relationships. I Ca,L was calculated as the difference between peak currents and the steady-state currents at the end of test pulse. B-c, Voltagedependency of steady-state activation and inactivation. Conductance G (V) was calculated by the equation: G(V)ϭI/ (V m ϪE rev ), where I is the peak currents, E rev is the measured reversal potential, and V m is the membrane potential. The normalized peak conductance was plotted against membrane potentials. Steady-state inactivation was estimated by a prepulse protocol (between Ϫ60 and 20 mV for 2 seconds). The normalized peak currents were plotted as a function of prepulse potentials. Steady demonstrate that the ZASP-binding proteins ␣-actinin-2 (ACNT2) directly binds and modulates Ca v 1.2, 10 whereas Na v 1.5 binds to and is regulated by the Z-line protein Telethonin/T-Cap. 9 Patch-clamp studies were carried out on both I Ca,L and I Na currents in isolated cardiomyocytes from 4-to 5-month-old NTG, WT, and S196L mouse hearts before the onset of hemodynamic dysfunction. Figure 4B -a shows superimposed I Ca,L traces obtained from the isolated cardiomyocytes of WT and S196L mice. The peak I Ca,L amplitude was reduced significantly in S196L cells compared with WT cardiomyocytes. The threshold and peak voltage of the I-V relationship were rightward shifted by approximately 15 mV ( Figure 4B-b) , leading to reduced calcium channel (Ca v 1.2) function. Figure 4B -c demonstrates that S196L rightwardshifted the voltage dependency of the steady-state activation and inactivation of I Ca,L . Table 2 summarized the biophysical parameters of I Ca,L obtained from at least 5 animals per line.
Because I Na has been reported to play an important role in cardiac conduction, characteristics of I Na were also studied in these mice. Figure 4C -a showed superimposed I Na traces obtained from the cardiomyocytes of WT or S196L mice. Although the peak current amplitude were similar between WT and S196L, S196L shifted the onset and peak currents of I-V relationships of I Na by 5 mV associated with a shift of the voltage-dependency of steady-state activation, which might affect phase 0 of the action potential ( Figure 4C-c and Table 2 ).
Our findings suggest that ZASP4 modulates both I Ca,L and I Na currents and therefore could physically interact with Ca v 1.2 and Na v 1.5. To evaluate this possibility, we used His-tagged ZASP4 and performed pull-down assays with neonatal rat cardiomyocyte lysates and demonstrated that ZASP4 pulls down both Ca v 1.2 and Na v 1.5, thus confirming that ZASP4 is part of these channels' macromolecular complex ( Figure 5 ). The pull-down assay confirms that ZASP is part of a protein complex including both Ca v 1.2 and Na v 1.5, but it is still unclear whether this interaction is direct. We performed coimmunoprecipitation and mammalian two hybrid analysis in HEK293 and C2C12 cells using both fulllength and ZASP ZM domains (Supplemental Methods), but there was no evidence of direct interaction between ZASP and either Ca v 1.2 or Na v 1.5 (data not shown). The functional modifications of the ion channels by S196L led us to investigate whether S196L could have affected Ca v 1.2 or Na v 1.5 function by altering their localization. However, confocal microscope immunohistochemistry images on NTG, WT, and S196L mice hearts demonstrated that both WT and Figure 6A-B) . These data provide a new structural basis to understand the effects of ZASP mutations on conduction disturbances in patients with DCM. Taken together, these studies demonstrate that mutation of ZASP4 targets 2 key ion currents in the myocardium and suggest that abnormalities of the ZASP protein underlie arrhythmias in patients with DCM.
Discussion
Defects in cytoskeletal proteins are a well-established cause of DCM, and altered ZASP represents a recent addition to the genetic heterogeneity of DCM and the complex regulation and maintenance of the contractile apparatus in striated cardiac muscle. In the present study, we used a mouse model to characterize the functional implications of the novel DCM-causing mutation in ZASP (S196L) previously identified in human subjects. 3 We showed that the expression of S196L in a cardiac-restricted manner recapitulates the DCM phenotype, consistent with the clinical presentation of the proband and affected relatives we previously described. 3 ECG abnormalities, such as conduction disturbances and AV block, appeared as early as 4 months, thus preceding functionally significant myocardial remodeling. We investigated the nature of these electrographic modifications and observed that S196L cardiomyocytes exhibited significant reduction in calcium influx from the L-type calcium channel Ca v 1.2 and a 10 mV rightward shift of the threshold and the peak voltage in the sodium channel I-V relationships. Although the Cav1.2 plays a small role in the propagation of normal cardiac tissues, its effects might increase significantly in diseased hearts when the Na v 1.5 function is impaired. 9, 17 It is reasonable to speculate that the concomitant reduction of Ca 2ϩ currents and impaired Na v 1.5 function might explain the cardiac conduction defects of the S196L mice. More detailed in silico analyses are warranted to link our biophysical data to the ECG phenotypes. Although S196L alters I Na and I Ca,L in our mouse model, other ion channels might be affected and contribute to the observed conduction defects. For example, a recent elegant study by Ueda et al 18 suggests that the hyperpolarization-activated channel 4 (HCN4), previously associated with sinus node dysfunction and preferentially expressed in the cells controlling the heart rate, is also expressed in the working myocardium. Genetic mutations of this channel can cause channel dysfunction, leading to conduction disturbances and ventricular arrhythmia.
Although we expressed the S196L mutation using the most significant cardiac-specific ZASP isoform background (ZASP4), [3] [4] [5] [6] both mice and humans express other ZASP isoforms containing exon 4, which would therefore include the S196L mutation. [3] [4] [5] [6] Thus, the S196L mutation in the ZASP4 isoform represents one of the mutant ZASP splice isoforms that could be affected and our findings may represent only the "tip of the iceberg" of the effects of ZASP mutations in the heart. This may explain why, contrary to what occurs in humans with DCM, we did not detect SCD in our mouse model.
To study the cardiac-specific effects of exon 4 mutation, we opted to generate transgenic mice overexpressing human ZASP4 cDNA because this transgene allows better conclusions about the role of the mutated human ZASP4 protein in vivo. In fact, despite a high degree of homology between ZASP4 and Cypher1c, there are significant differences in the protein sequence and structure of the murine and human ZM4 domains. Transgenic animals have been widely used to study the effects of genetic mutations in vivo, but knock-in mice containing the mutation in the conserved residue may provide a more physiological approach and will require additional future studies.
Our data indicate that altered calcium and sodium currents precede cardiac hemodynamic and structural changes and suggest that the ECG abnormalities may result directly from the effect of S196L on a cascade pathway involving Ca v 1.2 and Na v 1.5 as the ultimate targets. These findings are consistent with the observation that several patients with "compensated" heart failure are clinically stable with no evidence of symptoms such as fluid retention and pulmonary edema. Therefore, it is plausible that the S196L mouse hearts present ECG anomalies resulting from altered ion channels during the first months of life before obvious hemodynamic alterations. These findings might also imply that the ECG may represent an early diagnostic parameter in DCM subjects carrying this ZASP mutation.
We did not find evidence that the ZASP protein and the calcium and sodium channel proteins interact directly, but our data provide the first evidence that ZASP4 is part of a protein complex with them. In addition, S196L colocalized and complexed with Ca v 1.2 and Na v 1.5, in agreement with what occurs for mutant caveolin-3 (CAV3), 12,13 ␣-1-syntrophin (SNTA1), 14, 15 and T-Cap. 11 ZASP4 could perturb Ca v 1.2 and Na v 1.5 function through other Channel Interacting Proteins (ChIPs) such as the ZASP-binding proteins ACNT2, which modulate Ca v 1.2, 10, 20 and Telethonin/T-Cap, which regulates Na v 1.5. 9 We speculate that the effects of ZASP-S196L on the functions of Ca v 1.2 and Na v 1.5 are mediated by the ZASP-binding partner that physically interacts with these ion channels. This hypothesis is consistent with recent studies showing that perturbations of ChIPs may underlie the acquired disturbances of ion channels in cardiomyopathies and channelopathies. 10 -15,19,20 In the present study, we describe that the ZASP-S196L mutation affects the function of the ion channels. These findings may partly explain how loss-of-function mutations in SCN5A precipitate the development of conduction defects in DCM. 21, 22 However, further studies dissecting the detailed mechanism of the EP abnormality in S196L cardiomyocytes are warranted.
Although we have identified ZASP-S196L in DCM, other groups observed the same mutation in hypertrophic cardiomyopathy 23 and isolated noncompaction of the left ventricle. 24 It has been reported that patients with LV noncompaction present with an "undulating" phenotype from dilated to hypertrophic cardiomyopathy. 24 Therefore, it is possible that, in addition to the S196L mutation, other unknown genetic factors predispose human subjects to the clinical variability in their phenotypic presentation.
In conclusion, we present the first in vivo model of a ZASP-induced DCM recapitulating the clinical phenotype observed in human subjects. We present evidence that ZASP4 is part of a macromolecular complex including the ion channels Ca v 1.2 and Na v 1.5. This complex probably represents the structural basis of the electric disturbances of this DCM mouse model. Although the exact mechanism through which mutant ZASP4 alters calcium and sodium current remains elusive, we present evidence that cardiac-restricted expression of S196L is associated with cardiomyopathy and ECG abnormalities consistent with high risk of SCD.
